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Abstract
Mosquito-borne yellow fever virus (YFV) causes highly lethal, viscerotropic disease in humans and non-human primates.
Despite the availability of efficacious live-attenuated vaccine strains, 17D-204 and 17DD, derived by serial passage of
pathogenic YFV strain Asibi, YFV continues to pose a significant threat to human health. Neither the disease caused by wild-
type YFV, nor the molecular determinants of vaccine attenuation and immunogenicity, have been well characterized, in
large part due to the lack of a small animal model for viscerotropic YFV infection. Here, we describe a small animal model for
wild-type YFV that manifests clinical disease representative of that seen in primates without adaptation of the virus to the
host, which was required for the current hamster YF model. Investigation of the role of type I interferon (IFN-a/b)i n
protection of mice from viscerotropic YFV infection revealed that mice deficient in the IFN-a/b receptor (A129) or the STAT1
signaling molecule (STAT129) were highly susceptible to infection and disease, succumbing within 6–7 days. Importantly,
these animals developed viscerotropic disease reminiscent of human YF, instead of the encephalitic signs typically observed
in mice. Rapid viremic dissemination and extensive replication in visceral organs, spleen and liver, was associated with
severe pathologies in these tissues and dramatically elevated MCP-1 and IL-6 levels, suggestive of a cytokine storm. In
striking contrast, infection of A129 and STAT129 mice with the 17D-204 vaccine virus was subclinical, similar to
immunization in humans. Although, like wild-type YFV, 17D-204 virus amplified within regional lymph nodes and seeded a
serum viremia in A129 mice, infection of visceral organs was rarely established and rapidly cleared, possibly by type II IFN-
dependent mechanisms. The ability to establish systemic infection and cause viscerotropic disease in A129 mice correlated
with infectivity for A129-derived, but not WT129-derived, macrophages and dendritic cells in vitro, suggesting a role for
these cells in YFV pathogenesis. We conclude that the ability of wild-type YFV to evade and/or disable components of the
IFN-a/b response may be primate-specific such that infection of mice with a functional IFN-a/b antiviral response is
attenuated. Consequently, subcutaneous YFV infection of A129 mice represents a biologically relevant model for studying
viscerotropic infection and disease development following wild-type virus inoculation, as well as mechanisms of 17D-204
vaccine attenuation, without a requirement for adaptation of the virus.
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Introduction
Yellow fever virus (YFV) is the prototypic member of the genus
Flavivirus, family Flaviviridae; a group of arthropod-borne, positive-
sense RNA viruses which also holds dengue (DENV), West Nile
and Japanese encephalitis viruses [1]. YFV is endemic to tropical
Central and South America and sub-Saharan Africa where the
virus is mosquito-vectored between non-human primate (NHP)
reservoir hosts. Introduction into human populations results in
over 200,000 cases of yellow fever (YF) annually, with approxi-
mately 30,000 deaths [2]. Suspension of mosquito abatement
programs, decreasing vaccination coverage and recent problems
with vaccine safety and availability [3] have combined to make
YFV an emerging threat within the endemic zone and beyond, in
the southern United States, East Africa and previously unaffected
regions of South and Central America.
In humans, YF is a pansystemic viral sepsis with 20–50%
lethality, distinguishable from other viral hemorrhagic fevers
(VHF) by the appearance of hepatitis and jaundice [4]. Early ‘‘flu-
like’’ symptoms are followed by a brief period of remission, after
which some infections resolve without further complications:
however, illness may reappear in more severe form with high
fever, vomiting and epigastric pain. Effacement of the YFV-
infected liver is associated with hepatocyte apoptosis [5] and
severe, diffuse steatosis [6], disproportionate to the mild,
mononuclear inflammatory infiltrate [7]. Lymphoid tissues,
particularly the spleen, also suffer acute damage coincident with
the appearance of large, mononuclear cells and destruction of
follicles [6]. Hepatic-induced disseminated intravascular coagula-
tion (DIC) produces severe hemorrhagic manifestations. Late
central nervous system (CNS) manifestations, with confusion,
seizure and coma, combined with multiple organ failure, presage
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[4]. High elevation of pro- and anti-inflammatory cytokines,
particularly MCP-1, TNF-a and IL-6, during acute YF is strongly
correlated with hemorrhagic symptoms and fatal outcome [8],
suggesting a contribution to disease. The source of the cytokine
cascade is unknown, although it is believed that hepatocytes [5],
endothelial cells [9] and/or activated macrophages [4,10] may be
involved and immune clearance attempts may exacerbate viral
pathogenesis [4].
Treatment of YF is limited to symptomatic and supportive care,
as no specific antiviral drug is available [4]. Instead, our defense
against YFV relies primarily upon vaccination with the live-
attenuated YFV 17D substrains, 17D-204 and 17DD. To produce
the progenitor of modern-day 17D vaccines, wild-type Asibi strain
was empirically attenuated by serial passage in cultured cells [11].
Both the 17D-204 and 17DD vaccine substrains are considered
safe and highly efficacious, eliciting antibody-mediated, protective
immunity [3]. However, recent increases in the occurrence of fatal
vaccine-associated viscerotropic disease (YEL-AVD) have raised
concerns for the vaccine’s future [12]. Recently, several ground-
breaking studies have been published that begin to elucidate
immunologic correlates of protection following 17D immunization
[13–16] and disease in cases of YEL-AVD [17,18].
Our understanding of the mechanisms underlying the virulence
and pathogenesis of wild-type YFV, and the attenuation and
immunogenicity of the vaccine, is surprisingly limited given that
YFV was isolated in 1927 [11]. Existing knowledge comes primarily
from natural human infection [5,7,8,10,19,20] and NHP models of
viscerotropic disease [6,21], as small animal models have been
lacking that manifest clinical signs consistent with viscerotropism,
acute hepatitis and hemorrhagic fever [4]. Regardless of inoculation
route, wild-type and vaccine strains of YFV cause encephalitic
disease in mice, without apparent viscerotropism and, therefore,
lack relevance to human infection [4,22–26]. Golden hamsters
develop viscerotropic disease more closely resembling human YF,
butvirulencemustbe acquired by serial passage of wild-typeYFVin
vivo [27–30], limiting the application of this model to the study of
YFV pathogenesis. Herein, we describe our efforts to improve upon
the existing small animal YFV disease models.
Wild-type YFV likely possesses mechanisms to overcome or
circumvent innate immunity including type I (IFN-a/b) and/or
type II (IFN-c) interferon responses in human and NHP hosts,
similar to other flaviviruses [31–34]. Reasoning that this ability
might be primate-specific, we hypothesized that resistance of mice
to fatal viscerotropic YFV infection is mediated by IFNs as it
appears to be for DENV [35–37]. We have investigated the role of
IFN-a/b versus IFN-c in protection of mice against viscerotropic
YFV infection. Our data suggest that: i) wild-type YFV has little or
no ability to antagonize/evade the antiviral activity of IFN-a/b in
mice, since the type I IFN response provides absolute defense; ii)
evasion/antagonism of IFN-a/b antiviral activity may be pivotal
for virulence/disease in primate hosts, but may be species-specific;
and iii) the attenuated phenotype exhibited by 17D-204 virus
cannot be primarily attributed to IFN-a/b sensitivity since 17D-
204 virus remains attenuated in the absence of IFN-a/b signaling.
By eliminating IFN-a/b signaling in mice, we have produced a
model of wild-type YFV infection in which the virus causes
viscerotropic disease and fatality following subcutaneous inocula-
tion, but the vaccine strain remains attenuated.
Materials and Methods
Cell lines
Human Huh7 hepatocytes were maintained in Dulbecco’s
modified Eagle’s medium (DMEM), supplemented with 10% fetal
bovine serum (FBS), 0.29 mg/ml L-glutamine, 100 U/ml penicil-
lin and 0.05 mg/ml streptomycin (37uC; 5% CO2).
Virus stocks
Low-passage stocks of wild-type YFV strains Asibi and
Angola73, and the live-attenuated 17D-204 vaccine strain were
generously provided by Dr. Alan Barrett (University of Texas
Medical Branch, Galveston, TX). Since isolation the Asibi virus
strain was passed four times in monkeys, twice in suckling mice
and five times in Vero cells. The Angola73 virus was isolated
during an epidemic outbreak in Angola in 1973, and has
subsequently been passed three times in suckling mice and three
times in Vero cells. Both virus stocks were amplified once on Vero
cells for these studies. Virus particles were harvested from cell
culture supernatants when cytopathic effect was evident in the
culture, clarified by centrifugation and stored at 280uC in single-
use aliquots. Infectious virus titers were determined by plaque
assay on Huh7 cells, expressed as plaque forming units (PFU)/mL.
Mice
Mice deficient in receptors for IFN-a/b (A129) or IFN-c
(G129), both IFN-a/b and IFN-c receptors (AG129; [38]) or for
the STAT1 signaling molecule (STAT129; [39]) and congenic
control mice (WT129) were bred under specific pathogen-free
conditions. At 3–4 weeks old randomized male and female mice
were transferred to the ABSL-3 facility for infection. All
procedures were carried out in accordance with LSUHSC-S
Institutional Animal Care and Use Committee guidelines adhering
to protocols approved by the committee.
Mortality and pathogenesis studies
For morbidity/mortality studies, virus inocula containing 10
4
PFU of YFV Asibi, Angola73 or 17D-204 in 10 mL (i.e., 1610
6
PFU/mL) were administered to groups of at least four mice,
subcutaneously in both rear footpads. Mock-infected mice
Author Summary
The highly lethal viral hemorrhagic fever caused by the
mosquito-borne yellow fever virus (YFV) affects hundreds
of thousands of people annually, despite the availability of
the live-attenuated 17D vaccine, developed in the 1930s
by serial passage of wild-type strain Asibi. Our under-
standing of the molecular mechanisms controlling YFV
virulence and pathogenesis, and attenuation of the 17D
vaccine virus, is limited, with progress greatly impeded by
the lack of a small animal model reproducing human
disease. Here, we demonstrate that the wild-type Asibi
virus and 17D-204 vaccine substrain are readily distin-
guishable on the basis of morbidity, mortality and
pathogenesis when inoculated subcutaneously into mice
with deficiencies in their type I interferon (IFN-a/b) antiviral
response. In these animals, Asibi virus infection exhibits
pronounced viscerotropism, causing severe histopatholo-
gy in liver and spleen, correlated with dysregulated
cytokine induction, emulating hallmark features of human
YF. Importantly, 17D-204 virus infection of these mice is
rapidly self-limiting and subclinical as in human vaccinees.
This newly developed YF disease model can be exploited
to identify determinants of YFV virulence and reveal
molecular mechanisms that control the virus/host interac-
tion, providing a framework for rational design of acute
phase therapeutics and improved vaccines for protection
against YFV and other flaviviruses.
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intervals and weighed daily. Average survival time (AST), percent
mortality and weight changes were calculated.
For virus and cytokine titrations, groups of three mice per
treatment were euthanized by isofluorane-overdose, blood was
collected by cardiac puncture and serum was separated using
microtainer tubes (Becton-Dickinson). Mice were perfused with
PBS-1% DCS for 10 min at 7 mL/min to flush blood-borne virus.
Tissues were homogenized in PBS-1% DCS and clarified by
centrifugation (13,000 g, 15 min, 4uC). Serum and tissue homog-
enates were assayed for virus by Huh7 plaque assay. For histology,
three mice per treatment were euthanized, perfused with 4%
paraformaldehyde (PFA) in PBS (pH 7.4) and fixed in 4% PFA
(pH 7.4). Paraffin-embedded, hematoxylin and eosin (H&E)-
stained sections were viewed by light microscopy.
Cytokine and chemokine analyses
To measure MCP-1 and IL-6 levels, serum was analyzed by X-
Plex Cytokine Bead Array (BioPlex, BioRad) according to
manufacturer’s instructions. Briefly, serum was diluted 1:4 in serum
Figure 1. Virulence of wild-type YFV in mice is IFN-a/b-dependent while attenuation of live-attenuated 17D-204 virus is not. Adult
WT129 (solid line; open circle), G129 (solid line; open square), A129 (dotted line; closed circle), AG129 (dashed line; closed square) and STAT129 (dot-
dash line; closed triangle) mice were subcutaneously inoculated in each rear footpad with 10
4 PFU of wild-type YFV strains, Asibi (A and D) or
Angola73 (B and E) or with 17D-204 vaccine virus (C and F). Changes in weight from mock-infected counterparts were calculated daily for (A) Asibi
virus-infected, (B) Angola73 virus-infected or (C) 17D-204 virus-infected mice as an indicator of morbidity. Percent survivals of (D) Asibi virus-
infected, (E) Angola73 virus-infected and (F) 17D-204 virus-infected mice were calculated each day and are presented as Kaplan-Meier survival
curves. Datum points are n$4 and data are representative of at least two separate experiments.
doi:10.1371/journal.ppat.1000614.g001
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conjugated beads. Bead-bound cytokine molecules were detected
and quantified using biotinylated, cytokine-specific antibody and
streptavidin-PE. Reacted beads were fixed in 4% PFA to inactivate
residual virus, washed three times and resuspended in assay buffer
before analysis. Data were collected using flow cytometry-based
BioPlex Suspension Array and BioPlex Manager software calculat-
ed cytokine concentrations based on a standard curve.
Generation and infection of primary bone marrow-
derived DC and macrophage cultures
Primary bone marrow-derived DCs and macrophages were
generated as described previously [40]. Briefly, 8–12 week-old
mice were euthanized and bone marrow was aspirated from femur
and tibia bone shafts. After straining and pelleting, bone marrow
cells were resuspended in DC-competent medium (cRPMI 1640
supplemented with 10% FBS, 0.29 mg/mL L-glutamine, 100 U/
mL penicillin and 0.05 mg/mL streptomycin, 10 ng/mL GM-
CSF and 10 ng/mL IL-4) and incubated for 1 h (37uC; 5% CO2).
Non-adherent cells were removed and maintained in DC-
competent medium. Adherent cells were maintained in macro-
phage-competent medium (DMEM supplemented with 10% FBS,
0.29 mg/mL L-glutamine, 100 U/mL penicillin and 0.05 mg/mL
streptomycin, 20% L929-conditioned cell supernatant). Prior to
infection, non-adherent DCs were collected from supernatants and
adherent macrophages were scraped from plates. Cells were
washed, counted and seeded in V-bottom 96-well plates. Cells
were incubated with virus for 1 h, washed three times with PBS-
1% DCS and transferred to 24-well cell culture plates in 1 mL
appropriate growth medium. Samples were collected over the
course of infection and titered by Huh7 plaque assay.
Statistical analyses
All data were analyzed with GraphPad Prism software
(Graphpad Software, Inc). For survival analysis, Kaplan-Meier
survival curves were analyzed by the log-rank test. An unpaired
Student’s t-test was used to determine significant differences in
virus titers and cytokine levels.
Results
Wild-type YFV infection is fatal for type I IFN-deficient
mice, while live-attenuated 17D-204 vaccine strain is
avirulent
Groups of 3–4 week-old mice lacking receptors for IFN-a/b
(A129), IFN-c (G129), both IFN receptors (AG129) or lacking the
STAT1 signaling protein (STAT129) were inoculated subcutane-
ously in each rear footpad with 10
4 PFU of wild-type YFV strains,
Asibi or Angola73. Resulting morbidity and mortality were
compared to infection of WT129 animals (Fig. 1 and summarized
in Table 1). As expected, adult WT129 mice were disease-resistant
to either wild-type YFV strain, exhibiting neither morbidity, nor
mortality. Mice lacking IFN-c receptor-dependent responses were
no more susceptible to disease than controls (Fig. 1B and C)
suggestive that IFN-c was not required for protection against
virulent YFV infection.
In striking contrast, subcutaneous inoculation of mice deficient
in components of type I IFN signaling pathways with wild-type
Asibi or Angola73 viruses caused rapidly fatal infection (Fig. 1D
and E). A129 mice exhibited signs of illness by 3–4 d p.i. with
either virus, manifest as weight loss (Fig. 1A and B), lethargy,
piloerection and hunched posture, with generalized cachexia and
noticeable swelling at the inoculation site (not observed in WT129
animals). Animals deteriorated rapidly, becoming immobile and
weak, and were typically euthanized 7–8 d p.i. Asibi or Angola73
virus-infected AG129 mice typically developed disease and died
more rapidly than A129 counterparts suggestive that IFN-c
antiviral activity plays a compensatory or subordinate role to IFN-
a/b. Furthermore, deficiency in STAT1-dependent IFN signaling
did not render mice as susceptible as the combined absence of
IFN-a/b and IFN-c receptors or the IFN-a/b receptor only,
indicating a residual STAT1-independent antiviral response,
mediated by IFN-a/b and/or IFN-c. Importantly, none of the
Asibi or Angola73 virus-infected A129, G129 or STAT129 mice
developed any clinical signs typically associated with neurologic
disease such as ataxia, paresis or hind-limb paralysis. This differs
dramatically from existing small animal models of fatal wild-type
YFV infection, in which encephalitic paralysis is the major clinical
sign following intracerebral or peripheral inoculation [4].
In contrast to the wild-type viruses, subcutaneous inoculation of
A129 or STAT129 mice with the 17D-204 vaccine strain caused
no clinical signs of disease or mortality (Fig. 1C and F). The lack of
17D-204 virulence in these type I IFN-deficient mouse strains
suggests that attenuation of human virulence may not be solely a
result of altered sensitivity to IFN-a/b activity. Interestingly, 17D-
204 virus caused a uniformly fatal infection in AG129 mice,
consistent with the findings of Lee & Lobigs [41]. These data
signify that IFN-c is required to attenuate the vaccine in the
absence of the type I IFN response, likely in a largely STAT1-
independent manner as STAT129 mice survived without signs of
disease. However, the AST of 17D-204 virus-infected AG129 mice
was significantly longer than Asibi or Angola73 virus-infected
Table 1. Susceptibility of mice to subcutaneously inoculated Asibi and Angola73 wild-type or 17D-204 vaccine strains of yellow
fever virus.
WT129 G129 A129 AG129 STAT129
Asibi virus % mortality (dead/total) 0% (0/4) 0% (0/4) 100% (7/7) 100% (4/4) 100% (5/5)
AST6SD (d)
1 -
2 -6 . 4 60.8 5.560.0 7.861.6
Angola73 virus % mortality (dead/total) 0% (0/4) 0% (0/4) 100% (4/4) 100% (4/4) ND
3
AST6SD (d) - - 6.860.5 5.861.0 ND
17D-204 virus % mortality (dead/total) 0% (0/4) 0% (0/4) 0% (0/7) 100% (4/4) 0% (0/4)
AST6SD (d) - - - 10.161.4 -
1AST6SD (d): average survival time6standard deviation of the mean (days).
2- : not applicable.
3ND: Not done.
doi:10.1371/journal.ppat.1000614.t001
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that the vaccine strain remained relatively attenuated. Further-
more, 17D-204 virus-infected AG129 mice developed signs of
neurologic disease with paresis and paralysis, not seen in wild-type
YFV-infected counterparts, suggestive that neuroinvasion/neuro-
virulence of the vaccine strain in the absence of IFN-a/b and IFN-
c responses contributes to mortality.
Control of wild-type YFV replication and dissemination is
dramatically reduced in type I IFN-deficient mice
Since IFN-a/b controls replication and dissemination of many
viruses, including other flaviviruses [42–46], we reasoned that
increased susceptibility of type I IFN-deficient mice to wild-type
YFV infection would correspond to higher virus titers and
potentially altered tropism compared with 17D-204 virus infection
or wild-type YFV infection of disease-resistant WT129 mice. To
test this hypothesis, we focused upon the YF disease in mice
lacking the IFN-a/b receptor. WT129 and A129 mice were
inoculated subcutaneously with 10
4 PFU of Asibi or 17D-204 virus
and viral loads in serum and PBS-perfused tissues were measured
(Fig. 2). In parallel samples harvested from WT129 mice,
replication of neither Asibi, nor 17D-204, virus was detectable in
any tissue or at any time-point analyzed (data not shown).
Regional lymph nodes draining the inoculation site (DLN) are
an early amplification site for several other flaviviruses, important
for seeding the primary serum viremia and dissemination [47]. In
the absence of IFN-a/b-mediated antiviral responses, Asibi virus
amplified extensively in the popliteal DLN (Fig. 2A) and serum
viremia was detectable within 1 d p.i., increasing over the course
of infection (Fig. 2B). Asibi virus disseminated to the visceral
organs of A129 mice, represented by spleen and liver, within 1 d
p.i., reaching sustained levels of .10
7 PFU/g by 4 d p.i. (Fig. 2C
and D, respectively) and was also detected in bone aspirate
(Fig. 2E). Titration of whole brain homogenates revealed
detectable virus by 4 d p.i. (Fig. 2F). Due to the absence of
neurologic signs of disease, however, we speculate that replication
is predominately restricted to the meninges and/or endothelial
cells, sparing the brain parenchyma, similar to recent findings with
another non-encephalitic arbovirus, chikungunya virus [48].
Regardless, CNS replication is a late event, occurring after the
onset of clinical disease signs.
Consistent with morbidity/mortality results, 17D-204 virus
replication and dissemination were profoundly restricted in A129
mice (Fig. 2). While the vaccine virus was able to replicate in the
DLN in the absence of IFN-a/b responses, amplification was
delayed and reduced in comparison to parental Asibi virus
(Fig. 2A), peaking at almost 100-fold lower levels. Furthermore,
although the presence of a low-level serum viremia suggested that
17D-204 virus disseminated systemically (Fig. 2B), virus replication
was only sporadically detected beyond the DLN (Fig. 2C–F),
consistent with the lack of morbidity or mortality observed in 17D-
204 virus-infected A129 animals.
Wild-type YFV infection of type I IFN-deficient mice
induces proinflammatory cytokine release
In human YF and YEL-AVD, fatal hemorrhagic disease is
characterized by a systemic inflammatory response or ‘‘cytokine
storm,’’ with profoundly elevated serum levels of proinflammatory
cytokines and chemokines [8,18,49]. To determine whether or not
fatal Asibi virus infection of A129 mice similarly dysregulated the
inflammatory cytokine response, key inflammatory molecules were
measured in serum from Asibi virus-infected A129 and WT129
mice, and from 17D-204 virus-infected A129 mice (Fig. 3). ter
Figure 2. Wild-type Asibi virus exhibits viscerotropism in type I
IFN-deficient mice, whereas 17D-204 virus does not. WT129
(data not shown) and A129 mice were subcutaneously inoculated with
10
4 PFU of Asibi (black bar) or 17D-204 (white bar) virus in each rear
footpad. Viral titers in individual, perfused tissues are expressed as log10
PFU/ml of serum, PFU/draining lymph node (DLN) or PFU/g of other
tissues: (A) DLN; (B) serum; (C) spleen; (D) liver; (E) bone marrow; and
(F) brain. Dotted lines represent the lower limit of detection for the
plaque assay. Datum points are n=36SD for all data sets.
doi:10.1371/journal.ppat.1000614.g002
Viscerotropic YFV Infection in Mice
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levels of IL–6, MCP-1 and TNF-a were all statistically significantly
higher in patients with fatal, hemorrhagic YF than in those with
non-fatal YF. Consequently, we selected these cytokines for
analysis in our studies. Unfortunately, due to the necessity for
inactivation of virus in samples prior to analysis and the instability
of the TNF-a protein, neither ELISA nor BioPlex assays were
successful for this cytokine. Coincident with the onset of morbidity
4 d p.i., a hyper-inflammatory cytokine response was observed in
Asibi virus-infected A129 mice, with high levels of IL-6 (Fig. 4A)
and MCP-1 (Fig. 3B). Correlated with self-limiting, subclinical
infection, proinflammatory cytokine levels in Asibi virus-infected
WT129 mice and 17D-204 virus-infected A129 mice remained
around base-line throughout, consistent with the lack of
morbidity/mortality.
Wild-type YFV causes severe pathology in visceral organs
of type I IFN-deficient mice
Gross examination of organs from Asibi virus-infected A129
mice revealed evidence of hepatosplenomegaly by 4 d p.i., with
the livers appearing discolored and icteric, whereas organs from
17D-204 virus-infected A129 mice and Asibi virus-infected
WT129 mice appeared normal (data not shown). Tissues
harvested from Asibi virus-infected WT129 mice (data not shown)
or from 17D-204 virus-infected A129 mice were histologically
indistinguishable from mock-infected controls (Fig. 4A–D).
However, severe histopathologic changes were observed in visceral
organs from Asibi virus-infected A129 mice. At 4 d p.i., coincident
with disease onset and peak cytokine induction, lobular disarray of
the infected liver was observed with well-developed microvesicular
fatty acid steatosis involving much of the lobule parenchyma
(Fig. 4E and F). Spotty hepatocyte death was associated with
clusters of infiltrating inflammatory cells and, moreover, vascular
congestion and fibrin deposition were evident. By 6 d p.i., when
mice were moribund, focal inflammation of the portal triad was
observed, while the inflammatory infiltration and steatosis
remained essentially the same (Fig. 4G and H). Histopathologic
changes in the spleens of Asibi virus-infected A129 animals
consisted of dramatic follicular depletion accompanied by
lymphocytic necrosis within 4 d p.i. with loss of follicular
organization throughout, accompanied by an infiltration of
macrophages into white and particularly red pulp regions (Fig. 4I
and J). Similar, but more severe histopathology was observed by
6 d p.i. (Fig. 4K and L).
Infectivity for DCs and macrophages is IFN-a/b-
dependent and correlates with disease
Current models of YFV pathogenesis propose that infection of
DCsand/ormacrophagesmaybeacrucialearlyevent,inwhichthe
virus exploits migratory properties of activated cells to effect viremic
dissemination [4], similar to other arboviruses. Furthermore, these
cells may contribute to pathogenesis and cytokine induction [4,50–
52]. Accordingly, we have assessed the permissiveness of primary,
bone marrow-derived DCs and macrophages to infection with Asibi
and 17D-204 viruses in vitro (Fig. 5). DCs derived from either
WT129 or A129 mice supported the replication of Asibi virus
(Fig. 5A), with progeny virions detectable within 18 h p.i. and rising
to high titers. In contrast, DCs were virtually refractory to 17D-204
virus infection, regardless of their IFN-a/b competence (Fig. 5A),
although very low levels of progeny 17D-204 virus were detectable
in some experiments. Few progeny virions were released from
WT129-derived macrophages exposed to either Asibi or 17D-204
virus, but refractivity of macrophages was IFN-a/b signaling-
dependent, as both Asibi and 17D-204 viruses amplified efficiently
in A129-derived macrophages (Fig. 5B). Thus, it appears that
productive infection of both DCs and macrophages correlates with
fatal disease, since Asibi virus replicates in both DCs and
macrophages generated from A129 mice.
Discussion
Molecular mechanisms of YFV pathogenesis, virulence and
attenuation are not well understood, impeded by the lack of an
appropriate small animal model of viscerotropic YF disease caused
by the wild-type virus without the need for adaptation [4]. To
date, attempts to develop a mouse model of viscerotropic YFV
infection have been unsuccessful, with infected animals typically
exhibiting signs of encephalitic disease. To gauge the extent to
Figure 3. Cytokine levels are elevated in Asibi virus-infected A129 mice. Serum levels of (A) IL-6 and (B) MCP-1 were measured in serum
collected from mock-infected WT129 (open diamond) and A129 (closed diamond) mice, Asibi virus-infected WT129 (open circle) and A129 (closed
circle) mice and 17D-204 virus-infected A129 mice (closed square) by cytokine bead array analysis (BioRad BioPlex Assay). Data are expressed as
concentration of cytokine in pg/mL serum where datum points are n=36SD. Mock values were generated from pooled data over the course of
infection.
doi:10.1371/journal.ppat.1000614.g003
Viscerotropic YFV Infection in Mice
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YFV in mice, we evaluated YFV wild-type and vaccine infection in
animals lacking important components of the IFN-a/b and/or
IFN-c signaling pathways. Based upon our findings, we posit that
YFV infection of IFN-a/b receptor-deficient mice provides a
valuable small animal model, exhibiting key features of fatal
human YF following wild-type virus infection. Furthermore,
subcutaneous infection of A129 mice readily distinguishes virulent
wild-type YFV infection from the live-attenuated 17D-204 vaccine
strain. It should be noted that comparison to the established NHP
YF disease model will be important and beneficial to fully validate
the A129 model.
In the absence of type I IFN responses, wild-type Asibi virus
infection of A129 mice led to rapid viral dissemination, most likely
Figure 4. Pathologic changes were evident in liver and spleen of Asibi virus-infected A129 mice. A129 mice were mock-infected or
inoculated with 10
4 PFU of Asibi or 17D-204 viruses in each rear footpad. H&E-stained sections of liver and spleen are presented. Liver (A) and spleen
(B) sections from mock-infected A129 animals were indistinguishable from 17D-204-infected liver (C) and spleen (D) sections, 4 d p.i. (E and F) Liver
sections from Asibi virus-infected A129 mice 4 d p.i., showing diffuse inflammatory infiltrates, well-developed fatty acid steatosis involving the
majority of the lobular area. Note prominent Ku ¨pffer cells (black arrows) and some accumulation of inflammatory cells in hepatic sinusoids (arrow
heads). Original magnification: (E) 2006; (F) 4006. (G) Asibi virus-infected liver 6 d p.i., showing and a focus of spotty necrosis (center of field)
surrounded by mononuclear inflammatory cells and higher magnification (H) showing more severe inflammatory cell infiltration surrounding portal
triad and hepatocytes with intranuclear viral inclusion bodies (black arrows). Original magnification: (G) 2006; (H) 4006. (I and J) Spleen sections from
Asibi virus-infected A129 mice 4 d p.i. and (K and L) 6 d p.i., showing diminishing marginal zone (MZ) and white pulp lymphoid follicles (WP),
increasing number of splenic macrophages (arrow heads) and widely-distributed cells with pyknotic nuclei, morphologically consistent with
apoptotic death. Original magnification: (I, K, L) 2006; (J) 4006.
doi:10.1371/journal.ppat.1000614.g004
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phages, as described for other flaviviruses [37,53]. Asibi virus
amplified in the DLN, seeded a serum viremia and spread to other
tissues, notably exhibiting viscerotropism resembling human YF
[10]. In particular, the liver was a site of extensive Asibi virus
replication in A129 mice and suffered extensive damage, including
widespread fatty acid steatosis, mild inflammatory infiltration by
lymphocytes and macrophages, as well as apoptotic/necrotic
lesions, consistent with profound hepatic disease associated with
human YFV infections [4,6,10,19,20]. Similar hepatotropic
disease has also been observed in NHP with wild-type YFV
[6,21] and in hamster models, primarily using hamster-adapted
YFV strains [28]. Our study is the first to report viscerotropism
with histopathologic damage in a small animal model using native,
wild-type YFV strains.
Human YF disease is associated with a profound inflammatory
response in which serum concentrations of IL-6 and MCP-1, as
well as other cytokines, are significantly elevated and predictive for
severity of YF, distinguishing fatal hemorrhagic YF, non-fatal
hemorrhagic YF and non-fatal/non-hemorrhagic YF [8]. More-
over, in cases of fatal YEL-AVD, which resemble natural YF,
similar patterns of cytokine induction have been reported [18,49].
In Asibi virus-infected A129 mice IL-6 and MCP-1 were strongly
induced, peaking at 4 d p.i., coincident with the onset of disease.
Perhaps significantly, during trauma-hemorrhage and sepsis, two
disease etiologies with significant parallels to human YF, liver-
resident Ku ¨pffer macrophages are a major source of IL-6 and
MCP-1 [54]. These molecules act on immune cells leading to local
and generalized inflammation and affect vascular (endothelial)
function by modulating vascular nitric oxide and superoxide
release and mediating vascular disorders including shock and DIC.
Recent studies suggest that many factors contribute to YFV-
associated tissue damage in humans, including viral replication
and inflammatory cytokine mediators [7,20], which can be further
investigated in the A129 disease model prior to investigation in
NHP models.
Further validating this model of YF disease, attenuated 17D-204
virus infection of A129 animals was correlated with an apparently
abortive virus infection, greatly reduced viscerotropism and no
elevation of proinflammatory cytokines or tissue pathology. Thus,
the pathogenesis of 17D-204 virus was restricted compared with
the wild-type virus even in the absence of type I IFN activity. Since
17D-204 virus infected A129-derived DCs poorly in vitro, the
delayed appearance of 17D-204 virus in the DLN may reflect a
differential cell tropism and necessity to disseminate via a different
mechanism. Interestingly, A129-derived macrophages were per-
missive to 17D-204 virus infection in vitro and, therefore,
macrophages or an alternate DC subset may serve as a vehicle
for dissemination and amplification in vivo. The 17D-204 vaccine
strain triggers activation and maturation of human DCs in vitro via
multiple toll-like receptors [50,51], perhaps contributing to
immunogenicity in vaccinees. However, there is controversy as
to whether or not these cells are productively infected by 17D-204
virus [51,55], and their relative permissiveness to wild-type YFV
infection has not been assessed in vitro or in vivo. Our data suggest
that reduced ability to amplify in specific subsets of myeloid-
lineage cells may be one mechanism of 17D-204 attenuation;
however, further studies will be necessary to define the step(s) at
which 17D-204 virus infection is restricted compared to Asibi
virus, resulting in the attenuated phenotype; knowledge that will
facilitate the identification of molecular determinants of attenua-
tion and viscerotropic disease in YFV.
Finally, a central finding of this study is that YFV sensitivity to
murine IFN-a/b-mediated antiviral responses is sufficient to
protect against disease, while loss of the IFN response leads to
inflammatory, viscerotropic disease with striking similarities to
human YF and YEL-AVD. While the type I IFN response is
essential for protection in the mouse model, virulent human
infections occur in individuals with properly functioning IFN
responses. The apparent difference in efficacy between human and
murine IFN-a/b against YFV infection suggests a level of species-
specificity, where the human IFN-a/b response is significantly less
effective than murine in restricting YFV pathogenesis. Alterna-
tively, YFV may have evolved mechanisms to overcome or evade
IFN-a/b responses in natural primate hosts that are relatively
ineffective against murine IFN-a/b responses. Interestingly,
similarities to studies with DENV [35,37,46] and chikungunya
virus [48] suggest this phenomenon might be generally applicable
Figure 5. YFV strains Asibi and 17D exhibit differential infectivity for murine DCs and macrophages in vitro. Cultures of primary bone
marrow-derived DCs (A) and macrophages (B) generated from WT129 (circle) or A129 (triangle) mice were infected with wild-type Asibi virus (closed)
or live-attenuated 17D-204 virus (open) at MOI=0.1 PFU/cell. Viral replication was measured by plaque assay titration of progeny virions in culture
supernatants. Data are expressed as log10 PFU/mL where datum points are n=36SD. These data were reproducible in three separate experiments.
doi:10.1371/journal.ppat.1000614.g005
Viscerotropic YFV Infection in Mice
PLoS Pathogens | www.plospathogens.org 8 October 2009 | Volume 5 | Issue 10 | e1000614to mosquito-borne viruses that are restricted to primate reservoir
hosts in nature and non-encephalitic. More studies are necessary
to determine the differences in species specificity of IFN-a/b
responses on viruses like YFV. We anticipate that future studies
will better define the specific differences between infection of
humans and immune-competent mice. In the meantime, although
A129 mice may not perfectly model YFV infection of humans, we
believe they will be valuable for studying the virulence/attenuation
of YFV and developing hypotheses to be tested in focused non-
human primate studies.
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